Drug Profile
Research programme: CRISPR gene-edited CAR-T cell therapeutics - ToolGen
Latest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator ToolGen
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Cancer in South Korea (Parenteral)
- 31 Jul 2018 ToolGen has patent protection in South Korea and Australia
- 31 Jul 2018 ToolGen receives a notice of decision from EPO to grant patent for CRISPR/Cas9 genome editing system in European countries including Austria, Denmark, France, Germany, Italy, Netherlands, Spain, Sweden, and United Kingdom